GLP-1 Programme Data Readiness: A 12-Question Scorecard

A. Baseline and eligibility

0/3

Everything you later prove is a change from baseline, and eligibility rests on what was on file before treatment started.

1Do you record a measured weight, height and BMI at baseline, with a date and a label showing whether each figure was measured, external or self-reported?

Some payers judge eligibility on BMI at the start of GLP-1 therapy, so the starting figure has to stand up later.¹

Not yetFigures are mostly self-reported or undated

PartlyRecorded, but the source is not always clear

Yes, consistentlyDated, with the source labelled every time

2Is the evidence for each qualifying condition (for example a laboratory result or specialist letter) stored as structured data, not only as an attachment?

Payers ask for evidence behind each condition, not a tick box.

Not yetA tick box or free-text note

PartlyDocuments are attached but not structured

Yes, consistentlyStructured and linked to the source document

3When patients bring laboratory reports from other providers, are the results captured as structured values with units, dates and reference ranges?

Outside reports arrive in many formats and languages, and are often the only baseline blood tests you have.

Not yetThey stay as PDFs or photos

PartlyKey values are typed in by hand

Yes, consistentlyStructured, with units, dates and ranges kept

B. Treatment and safety

0/3

Safe prescribing and honest outcome reporting both depend on knowing exactly what each person took, and what happened.

4Do you hold a complete dose and product history for each patient, including pauses, switches between medicines, and branded versus generic products?

Without it, a plateau in weight loss can look like a treatment failure when it was a supply gap.

Not yetOnly the current prescription

PartlyDose steps, but not pauses or switches

Yes, consistentlyFull history, including treatment elsewhere

5Is safety history recorded as structured fields, for example personal or family history of medullary thyroid carcinoma or MEN 2 as yes, no or unknown?

Both semaglutide and tirzepatide are contraindicated with this history in their US labels.^{2, 3}

Not yetCaptured in free text, if at all

PartlySome fields, but blanks are allowed

Yes, consistentlyStructured, with no blanks allowed

6Are side effects, dose reductions, emergency visits and admissions recorded as structured events, including those found in discharge summaries and letters?

The most important safety information often arrives in documents from other providers.

Not yetMostly in chat or call notes

PartlyOur own events are coded, outside ones are not

Yes, consistentlyAll events coded, with dates and source

C. Monitoring and outcomes

0/3

Between appointments, home readings and follow-up checkpoints are how you know whether the programme is working.

7Does every home reading carry its unit, the time it was taken, the person it belongs to, and the source photo or device record?

A weight with no unit or date will not survive a payer review.

Not yetNumbers typed in, little context

PartlyConnected devices only, photos not handled

Yes, consistentlyAll routes, with full context

8Do you measure every patient at the same checkpoints (for example 3, 6 and 12 months) against a written response rule?

NICE, for example, advises considering stopping semaglutide if less than 5% of initial weight has been lost after 6 months.⁴

Not yetFollow-up varies by clinician

PartlyCheckpoints exist, but no written rule

Yes, consistentlyFixed checkpoints and a written rule

9Can you report persistence with a stated definition, and the reason each person stopped, using a fixed list of reasons?

In one large US study, most people without type 2 diabetes stopped within a year.⁵

Not yetWe could not say how many stopped

PartlyWe know who stopped, not why

Yes, consistentlyDefined rate and coded reasons

D. Reporting and governance

0/3

The final test is whether you can share the right evidence with the right party, quickly and lawfully.

10Can you produce an outcomes report for each payer or sponsor without a manual spreadsheet exercise?

Employers, insurers and public payers each want a different cut of the same data.

Not yetEach report is built by hand

PartlySome reports are automated

Yes, consistentlyReports come from the same structured data

11Does your consent cover each way the data is used, and do you share data with sponsors in pseudonymised form?

A programme often serves the patient, a paying sponsor and sometimes research, each needing a clear basis.

Not yetOne general consent, identifiable sharing

PartlyClear consent, but sharing is not pseudonymised

Yes, consistentlySpecific consent and pseudonymised sharing

12Do you know where every piece of your programme's data is processed, and does that meet each market's rules on in-country processing?

For many buyers and regulators, in-country processing is now one of the first questions asked.

Not yetWe are not sure where all of it goes

PartlyMapped, but not checked against each market

Yes, consistentlyMapped and checked for every market we serve

Your score

Answer the questions above and your score will build here as you go.

0 / 24

Not started

A. Baseline and eligibility

0/6

B. Treatment and safety

0/6

C. Monitoring and outcomes

0/6

D. Reporting and governance

0/6

Band	Score	What it usually means
Foundations first	0 to 8	Key records are missing or locked in documents. Payer questions will be hard to answer today.
Building	9 to 16	The basics are in place, with gaps that will show up under audit or in a sponsor review.
Payer-ready	17 to 24	Your data can support eligibility, safety and outcome claims. Focus on any area below 4.

How Ready Is Your GLP-1 Programme's Data? A 12-Question Scorecard

How the scoring works

How Jonda Health can help

References

Try JondaX free